Pancreatic cancer drug shows 41% response rate in clinical trial

9 hours ago 1
Read Entire Article
  1. Homepage
  2. Finance
  3. Pancreatic cancer drug shows 41% response rate in clinical trial

Related

Like Jeff Bezos and Howard Schultz, Chess.com’s cofounder says people doubted his vision—with a 225 million-user empire, he’s now having the last laugh

Like Jeff Bezos and Howard Schultz, Chess.com’s cofounder sa...

55 minutes ago 0
Sam Altman wants to ‘treat adults like adults’—but can OpenAI keep ChatGPT safe after opening the door to erotica?

Sam Altman wants to ‘treat adults like adults’—but can OpenA...

1 hour ago 0
An ex-OpenAI researcher’s study of a million-word ChatGPT conversation shows how quickly ‘AI psychosis’ can take hold—and how chatbots can sidestep safety guardrails

An ex-OpenAI researcher’s study of a million-word ChatGPT co...

1 hour ago 0
CEO coach to the Fortune 500: The best leaders have developed a surprising talent—they know how to be ‘actively’ lazy

CEO coach to the Fortune 500: The best leaders have develope...

2 hours ago 0
Meghan, Duchess of Sussex, on work-life balance as a CEO: ‘I’m still going to chaperone the first-grade field trip’

Meghan, Duchess of Sussex, on work-life balance as a CEO: ‘I...

2 hours ago 1
Teacher education roadmap seeks to address specialization mismatch 

Teacher education roadmap seeks to address specialization mi...

4 hours ago 0
PHIVOLCS warns against going up to a higher floor during an earthquake 

PHIVOLCS warns against going up to a higher floor during an ...

5 hours ago 1
PHIVOLCS: Surigao quake triggered by Philippine Trench, unrelated to Davao tremors 

PHIVOLCS: Surigao quake triggered by Philippine Trench, unre...

5 hours ago 1
InvestingPro Fair Value alert yields 65% return on Janus International stock

InvestingPro Fair Value alert yields 65% return on Janus Int...

6 hours ago 0
Kingsoft Cloud shares drop 40% after InvestingPro’s overvaluation alert

Kingsoft Cloud shares drop 40% after InvestingPro’s overvalu...

6 hours ago 0
China's Xi calls for 'reunification' in message to new Taiwan opposition leader

China's Xi calls for 'reunification' in message to new Taiwa...

7 hours ago 0
Thieves steal jewels from Louvre in Paris, media reports

Thieves steal jewels from Louvre in Paris, media reports

7 hours ago 0
UK's Prince Andrew asked police to help smear sexual abuse accuser, newspaper says

UK's Prince Andrew asked police to help smear sexual abuse a...

7 hours ago 0
ICICI Bank ADR earnings missed, revenue fell short of estimates

ICICI Bank ADR earnings missed, revenue fell short of estima...

7 hours ago 0
Ex-French President Sarkozy says 'not afraid' ahead of jail term

Ex-French President Sarkozy says 'not afraid' ahead of jail ...

7 hours ago 0
HDFC Bank ADR earnings missed, revenue fell short of estimates

HDFC Bank ADR earnings missed, revenue fell short of estimat...

7 hours ago 0
Looking for a way forward, Democrats zero in on affordability

Looking for a way forward, Democrats zero in on affordabilit...

7 hours ago 0
US-China trade war clouds global economic outlook as ’new normal’ emerges

US-China trade war clouds global economic outlook as ’new no...

7 hours ago 0
After army coup, Madagascar's Gen Z demand a voice in shaping what comes next

After army coup, Madagascar's Gen Z demand a voice in shapin...

7 hours ago 0
Japan in focus: Can Sanae Takaichi secure premiership in upcoming vote?

Japan in focus: Can Sanae Takaichi secure premiership in upc...

8 hours ago 0

Trending

1. charan boro
2. nse holiday 2025
3. rangoli easy
4. vikram
5. sophie ecclestone
6. elche vs athletic club
7. rangoli diwali
8. louvre museum
9. fifa u20 world cup
10. heather knight

Popular

Gold ETFs see 6-fold jump in September inflows: What's driving surge?

Gold ETFs see 6-fold jump in September inflows: What's ...

3 days ago 5
GoodRx launches subscription program for men's hair loss

GoodRx launches subscription program for men's hair loss

3 days ago 5
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© FBT Company 2025. All rights are reserved